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Abstract 29 
There is conflicting evidence on whether dietary nitrate supplementation can improve 30 
exercise performance. This may arise from the complex nature of nitric oxide (NO) 31 
metabolism which causes substantial inter-individual variability, within-person biological 32 
variation (CVB), and analytical imprecision (CVA) in experimental endpoints. However, no 33 
study has quantified the CVA and CVB of NO metabolites or the factors that influence their 34 
production. These data are important to calculate the critical difference (CD), defined as the 35 
smallest difference between sequential measurements required to signify a true change. The 36 
main aim of the study was to evaluate the CVB, CVA, and CD for markers of NO availability 37 
(nitrate and nitrite) in plasma and saliva before and after the ingestion of nitrate-rich beetroot 38 
juice (BR). We also assessed the CVB of nitrate-reducing bacteria from the dorsal surface of 39 
the tongue. It was hypothesised that there would be substantial CVB in markers of NO 40 
availability and the abundance of nitrate-reducing bacteria. Ten healthy male participants 41 
(age 25 ± 5 years) completed three identical trials at least 6 days apart. Blood and saliva were 42 
collected before and after (2, 2.5 and 3 h) ingestion of 140 ml of BR (~12.4 mmol nitrate) and 43 
analysed for [nitrate] and [nitrite]. The tongue was scraped and the abundance of nitrate-44 
reducing bacterial species were analysed using 16S rRNA next generation sequencing. There 45 
was substantial CVB for baseline concentrations of plasma (nitrate 11.9%, nitrite 9.0%) and 46 
salivary (nitrate 15.3%, nitrite 32.5%) NO markers. Following BR ingestion, the CVB for 47 
nitrate (plasma 3.8%, saliva 12.0%) and salivary nitrite (24.5%) were lower than baseline, but 48 
higher for plasma nitrite (18.6%). The CD thresholds that need to be exceeded to ensure a 49 
meaningful change from baseline are 25, 19, 37, and 87% for plasma nitrate, plasma nitrite, 50 
salivary nitrate, and salivary nitrite, respectively. The CVB for selected nitrate-reducing 51 
bacteria detected were: Prevotella melaninogenica (37%), Veillonella dispar (35%), 52 
Haemophilus parainfluenzae (79%), Neisseria subflava (70%), Veillonella parvula (43%), 53 
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Rothia mucilaginosa (60%), and Rothia dentocariosa (132%). There is profound CVB in the 54 
abundance of nitrate-reducing bacteria on the tongue and the concentration of NO markers in 55 
human saliva and plasma. Where these parameters are of interest following experimental 56 
intervention, the CD values presented in this study will allow researchers to interpret the 57 
meaningfulness of the magnitude of the change from baseline.   58 
Key Words: beetroot juice; nitrite; microbiome 59 
 60 
Highlights 61 
• Concentration of nitric oxide markers varies considerably between individuals 62 
• Nitric oxide markers are subject to substantial biological variation 63 
• Pharmacokinetics following nitrate supplementation can vary within individuals 64 
• Variation in bacteria only partly account for variability in nitric oxide markers   65 
• Critical difference values presented herein will aid interpretation of nitric oxide data 66 
  67 
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1. Introduction  68 
Dietary nitrate (NO3
-) supplementation increases the concentration of nitric oxide (NO) 69 
metabolites within the blood (Kapil et al. 2010). Crucial to this process is the reduction of 70 
concentrated NO3
- in saliva (Lundberg and Govoni 2004) to nitrite (NO2
-) by facultative 71 
anaerobic bacteria in the oral cavity (Duncan et al. 1995). The importance of this mechanism 72 
to cardiovascular health is evident in the breadth of research showing that ingestion of 73 
inorganic NO3
- acutely lowers blood pressure (Webb et al. 2008; Siervo and Lara 2013). 74 
Elevations in plasma NO2
- have been associated with decreased cardiovascular risks factors 75 
and increased exercise capacity in healthy and chronically diseased cohorts (Kleinbongard et 76 
al. 2006; Allen et al. 2010; Totzeck et al. 2012). Dietary NO3
- supplementation has also been 77 
shown to improve time trial (Lansley et al. 2011; Muggeridge et al. 2014) and intermittent 78 
(Wylie et al. 2013) exercise performance. However, some studies report no ergogenic effects 79 
(Peacock et al. 2012; MacLeod et al. 2015) and, taken as a whole, the effects of dietary NO3
- 80 
supplementation on exercise performance outcomes appear to be equivocal (McMahon et al. 81 
2017). One hypothesis that may account for the lack of consensus across the literature is that 82 
individuals respond differently to NO3
- supplementation (Porcelli et al. 2015). Indeed, there 83 
appears to be substantial inter-individual variability in plasma [NO3
-] and [NO2
-] 84 
pharmacokinetics before and after NO3
- administration (James et al. 2015). For example, we 85 
have previously shown that the increase in plasma [NO2
-] can range from 80 to 400 nM with 86 
a time-to-peak ranging from 1.5 to 6 h following ingestion of NO3
- supplements (McIlvenna 87 
et al. 2017). 88 
 89 
Surprisingly, the within-individual variability in NO metabolites, either at basal 90 
concentrations or following ingestion of NO3
-, has not been reported in the literature. This is 91 
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important as there are several potential factors that could affect both the intra- and inter-92 
individual variability of circulating [NO3
-] and [NO2
-]. These factors include, but are not 93 
limited to: posture during blood collection (Liddle et al. 2018), prior sunlight exposure 94 
(Monaghan et al. 2018), the NO3
- and  NO2
- content of the diet (Bryan et al. 2007), the rate of 95 
endogenous NO synthesis, NO3
- transport in the salivary glands (Lundberg 2012; Qin et al. 96 
2012), the abundance of  NO3
--reducing bacteria in the mouth (Burleigh et al. 2018), salivary 97 
flow-rate (Webb et al. 2008), the rate of NO3
- and NO2
- reduction in the gut (Lundberg et al. 98 
1994), urinary excretion rates (Pannala et al. 2003), and training status (Porcelli et al. 2015). 99 
Whilst it is impossible to control all of the factors that influence the concentration of 100 
circulating NO metabolites, it is important to understand the extent to which they can vary 101 
within the same individual and the analytical error (CVA) associated with their measurement.  102 
 103 
The within-individual or biological variation (CVB) establishes the inherent fluctuations 104 
around a homeostatic set-point of a measured variable (Harris 1970). The CVB can be used in 105 
combination with the CVA to calculate the critical difference (CD) which is defined as the 106 
change from baseline that must occur before a meaningful biological difference can be 107 
claimed (Fraser and Fogarty 1989). In short, a researcher is able to use the CVB and the CVA 108 
to determine the typical “noise” in the variable of interest. The CD provides a single criterion 109 
threshold which, if exceeded, they can conclude a true change has occurred in response to 110 
any intervention.  For reference, it has been previously reported that serum cholesterol has a 111 
CVB of 7.6% and a CD of 17.2% (Fraser 2001). Blood glucose has been shown to have a 112 
CVB and CD of 7.2% and 14.9%, respectively (Widjaja et al. 1999). In the context of dietary 113 
NO3
- supplementation researchers must first be confident that the intervention results in a true 114 
increase in NO availability if there is to be potential for any ergogenic effect.   115 
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To our knowledge, the CD values of NO3
- and NO2
- in plasma, saliva, and urine at baseline 116 
and in response to NO3
- have not been previously reported. Likewise, despite recognition of 117 
the importance of NO3
--reducing bacteria for the generation of NO through the NO3
--NO2
--118 
NO pathway, no study has quantified the CVB in the abundance of these bacteria in the oral 119 
cavity. Therefore, the primary aim was to quantify the CVB and CD of the abundance of NO3
-120 
-reducing bacteria, blood pressure, and plasma, saliva, and urine [NO3
-] and [NO2
-] before 121 
and after ingestion of NO3
--rich beetroot juice (BR). A secondary aim was to determine 122 
whether the variation in these NO metabolites was associated with the abundance of NO3
--123 
reducing bacteria. It was hypothesised that there would be substantial CVB of the abundance 124 
of NO3
--reducing bacteria and the concentration of NO metabolites in plasma, saliva, and 125 
urine. Further, it was hypothesised that the variations in plasma and salivary [NO3
-] and 126 
[NO2
-] would be positively associated with the abundance NO3
--reducing bacteria. 127 
 128 
2. Methods 129 
2.1. Participants 130 
Ten healthy and recreationally active male participants (age 25 ± 5 years, stature 177 ± 5 cm, 131 
and body mass 81 ± 11 kg) volunteered to participate in the study and provided written 132 
informed consent. The study was approved by the School of Science and Sport Ethics 133 
Committee at The University of the West of Scotland and all procedures were performed in 134 
accordance with the 1964 Declaration of Helsinki and its later amendments. 135 
 136 
 137 
 138 
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2.2. Study design 139 
Each participant attended the laboratory on three separate occasions with 6-10 days between 140 
each visit. Each trial comprised a 3.5 h period where participants lay supine and repeated 141 
samples of biological fluids were collected and blood pressure was measured. The 142 
experimental conditions were identical in each visit. Following the collection of baseline 143 
measurements, participants immediately ingested 2 x 70 ml of BR (Beet It SPORT, James 144 
White Drinks, UK; total of ~12.4 mmol NO3
-). Participants were instructed to avoid caffeine, 145 
foods high in NO2
- and NO3
- (e.g. green leafy vegetables and cured meats), alcohol, and 146 
strenuous exercise in the 24 h prior to the experiment. Participants were also asked to avoid 147 
mouthwash 7 days prior to the first trial and for the duration of the study. All participants 148 
confirmed that they were not using medication of any kind for a month before the first trial or 149 
at any point during the study period. Participants were also asked to refrain from brushing 150 
their teeth and tongue on the morning of each lab visit. Participants recorded dietary intake 151 
and the modality, frequency, and intensity of exercise undertaken 72 h prior to the first 152 
experimental trial and replicated this for the subsequent visits. Participants were provided 153 
access to bottled water (Strathrowan Scottish Mountain water, Aldi Stores Ltd, Ireland) to 154 
consume ad libitum during the first visit. The volume of water and the time of ingestion was 155 
recorded during the first visit and matched for subsequent trials.  156 
 157 
2.3. Procedures 158 
A schematic of the experimental procedures is provided in Figure 1. Following standard 159 
anthropometric measurements (stature and body mass), participants lay in a supine position to 160 
allow the insertion of a cannula into the antecubital vein. Following cannulation, participants 161 
continued to lay in a supine position for a total of 30 min before baseline samples of venous 162 
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blood and saliva were collected. Baseline blood pressure was then recorded in triplicate by 163 
using an automated oscillometric device (Omron 705IT, Omron Global. Hoofddorp, 164 
Netherlands). Mean arterial pressure (MAP) was calculated using the following equation: 165 
 166 
MAP = (2 x diastolic blood pressure + systolic blood pressure) / 3 167 
 168 
Venous blood (4 ml) was collected in EDTA vacutainers (BD vacutainer K2E 7.2mg, 169 
Plymouth, U.K.) and the cannula flushed with sterile 0.9% saline solution between samples to 170 
keep the line patent. The vacutainer was centrifuged (Harrier 18/80, Henderson Biomedical, 171 
UK) at 4000 rpm for 10 min at 4oC immediately after collection (Pelletier et al. 2006). 172 
Plasma was then separated, frozen at −80°C, and analysed within 4 months (Pinder et al. 173 
2009) of initial collection for determination of [NO3
-] and [NO2
-].  Samples of unstimulated 174 
saliva were collected via a non-cotton polymer oral swab (Saliva Bio Oral Swab (SOS) 175 
Salimetrics, Pennsylvania, USA) placed under the tongue for 2 min. Swabs were then 176 
transferred to a collection tube (Sarstedt, Aktiengesellschaft & Co, Numbrecht, Germany) 177 
and centrifuged at 4000 rpm for 10 min at 4°C. Samples were separated into two cryovials 178 
and immediately stored at −80⁰C for later analysis of [NO3-] and [NO2-]. Swabs were used to 179 
collect saliva samples in preference to the “passive drool” technique in an attempt to improve 180 
the consistency of saliva collection within and between participants.  181 
 182 
Participants were then instructed to sit up to allow for the collection of a bacterial sample 183 
from the posterior dorsal surface of the tongue using a sterile stainless-steel metal tongue 184 
cleaner (Soul Genie, Health Pathways LLP, India). The tongue cleaner was scraped over the 185 
dorsal surface of the tongue 3-5 times or until there was a visible coating on the instrument. A 186 
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sterile collection swab (Deltalab, S.L. Barcelona, Spain) was then used to collect the bacteria 187 
from the tongue cleaner before being placed into a PowerSoil Bead Tube (MoBio 188 
Laboratories Inc., West Carlsbad, California) and immediately frozen at −80oC for later 189 
isolation of DNA, as per the manufacturer’s instructions. Participants were then requested to 190 
void their bladder and a sample of urine was frozen at −80 °C for later analysis of [NO3-]. 191 
The volume of all further bladder voids were recorded following ingestion of BR to allow for 192 
the calculation of total NO3
- excretion using the following equation:  193 
 194 
Total NO3
- excretion (g) = NO3
- (M) * urine volume (L) 195 
 196 
Repeated measurements of blood pressure and collection of saliva, blood, and urine samples 197 
were collected at various subsequent time points as detailed in Figure 1. All blood samples 198 
were collected when participants were supine to allow plasma [NO2
-] to stabilise following 199 
postural alterations. Blood pressure was also measured when participants were supine to 200 
ensure measurements were time-aligned with plasma [NO2
-] and [NO2
-].  201 
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 202 
 203 
Figure. 1.  Schematic of measurement time points for all trials. Dashed arrows depict optional 204 
urine collection.   205 
 206 
2.4. Plasma nitrate and nitrite analysis 207 
Measurements of [NO3
-] and [NO2
-] were conducted using ozone-based chemiluminescence 208 
(Rogers et al. 2005). For the measurement of plasma [NO3
-], vanadium reagent (24 mg of 209 
vanadium tri-chloride and 3 ml of 1M Hydrochloric acid) and 100 μL of anti-foaming agent 210 
were placed into a customised glass purge vessel infused with nitrogen and heated to 95°C. 211 
This purge vessel was connected to an NO analyser (Sievers NOA 280i, Analytix, UK). A 212 
standard curve was produced by injecting 25 μL of NO3- solutions (100 μM, 50 μM, 25 μM, 213 
12.5 μM, and 6.25 μM) and a control sample containing deionised water. The area under the 214 
curve (AUC) for the latter was subtracted from the NO3
- solutions to account for NO3
- in the 215 
water used for dilutions. Plasma samples were thawed in a water bath at 37°C for 3 min and 216 
de-proteinised using zinc sulphate/sodium hydroxide solution (200 μL of plasma, 400 μL of 217 
zinc sulphate in deionised water at 10% w/v and 400 μL of 0.5M sodium hydroxide). The 218 
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samples were then vortexed for 30 s and remained at room temperature for 15 min before 219 
being spun at 4000 rpm for 5 min. Subsequently, 15-25 μL of the sample was injected into 220 
the purge vessel in duplicate. The concentration of NO cleaved during the reaction was then 221 
measured by the NO analyser. The AUC was calculated using Origin software (version 7) 222 
and divided by the gradient of the slope. 223 
 224 
For the measurement of plasma [NO2
-], tri-iodide reagent (2.5 ml glacial acetic acid, 0.5 ml 225 
of 18 Ω deionised water and 25 mg sodium iodide) and 100 μL of anti-foaming agent were 226 
placed into the glass purge vessel and heated to 50°C. A standard curve was produced by 227 
injecting 100 μL of NO2- solutions (1000 nM, 500 nM, 250 nM, 125 nM, and 62.5 nM) and a 228 
control sample of deionised water. The AUC for the latter was subtracted from the NO2
- 229 
solutions to account for NO2
- in the water used for dilutions.  Following this, plasma samples 230 
were thawed in a water bath and 100 μL of the sample was injected into the purge vessel in 231 
duplicate and [NO2
-] was determined via the AUC, as previously described.  232 
 233 
2.5. Salivary nitrite and nitrate analysis  234 
The same reagents used for plasma [NO3
-] and [NO2
-] analyses were used for the analysis of 235 
salivary metabolites. The standard curve for salivary [NO3
-] was the same as described for 236 
plasma [NO3
-]. The standard curve for salivary [NO2
-] was produced by injecting 100 μL 237 
NO2
- solutions up to 5 μM. For both metabolites, saliva samples were thawed as previously 238 
described and then diluted at a ratio of 1:100 with deionised water. Subsequently, 100 μL of 239 
the sample was injected for the measurement of [NO2
-] and 10-25 μL for [NO3-]. Samples 240 
were injected into the purge vessel in duplicate and calculated as previously described before 241 
being corrected for the dilution factor. 242 
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2.6. Urinary nitrate analysis 243 
The same reagent and standard curve used for plasma [NO3
-] analysis was used for the 244 
measurement of urinary [NO3
-]. Urine samples were thawed and diluted at a ratio of 1:100 245 
with deionised water. Following this, 15-25 μL of the sample was injected to the purge vessel 246 
in duplicate and [NO3
-] calculated as previously described.  247 
 248 
2.7. Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) 249 
DNA samples were transported to a commercial centre (HOMMINGS, The Forsyth Institute, 250 
Boston MA, USA) for sequencing analysis. A full description of the protocol is described by 251 
Caporaso et al. (2011). In brief, the V3-V4 region of the bacterial genomic DNA was 252 
amplified using barcoded primers; ~341F (forward [oligonucleotide] primer) 253 
AATGATACGGCGACCACCGAGATCTACACTATGGTAATTGTCCTACGGGAGGCA254 
GCAG and ~806R (reverse primer) 255 
CAAGCAGAAGACGGCATACGAGATNNNNNNNNNNNNAGTCAGTCAGCCGGACT256 
ACHVGGGTWTCTAAT. Samples (10 – 50 ng) of DNA were amplified by polymerase 257 
chain reaction using V3-V4 primers and 5 PrimeHotMaster Mix and purified using AMPure 258 
beads. A small volume (100 ng) of each library was pooled, gel-purified, and quantified using 259 
a bioanalyser and qPCR. Finally, 12pM of the library mixture, spiked with 20% Phix, was 260 
analysed on the Illumina MiSeq (Illumina, San Diego, CA). 261 
 262 
2.8. 16s rRNA gene data analysis  263 
Quality filtered data received from the sequencing centre was further analysed for taxonomic 264 
classification and bacterial abundance using Qiime 1.8 (Caporaso et al. 2010). One sample with 265 
less than 5000 reads was discarded from further analysis. Sequences were clustered de novo 266 
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and binned into operational taxonomic units (OTU) based on 97% identity. Taxonomy was 267 
assigned using RDP classifier trained to the GreenGenes database (October 2013 release). 268 
Singleton reads were removed from the dataset. In order to calculate alpha diversity metrics, 269 
the OTU table was sub-sampled to 14870 reads per sample and repeated 5 times. The mean 270 
values were then calculated across the 5 sub-sampled OTU tables and used to calculate alpha 271 
diversity metrics. Alpha diversity metrics were calculated using the Shannon diversity 272 
equation, which accounts for the richness and evenness of species in a sample. The smallest 273 
number of reads associated with any one sample was 14870 reads. These analyses enabled 274 
the calculation of the abundance of bacteria at the specific genus and species level that have 275 
been previously reported to reduce NO3
- in the oral cavity (Doel et al. 2005; Hyde et al. 276 
2014a). The sum of the abundance of NO3
--reducing bacteria was also calculated and used in 277 
further analysis.  278 
 279 
2.9. Statistical analysis 280 
All analyses were carried out using the Statistical Package for Social Sciences, Version 22 281 
(SPSS Inc., Chicago, IL, USA). GraphPad Prism version 7 (GraphPad Software Inc., San 282 
Diego, USA) was used to create the figures. Data are expressed as the mean ± standard 283 
deviation (SD). The distribution of the data were tested using the Shapiro-Wilk test. A two-284 
way repeated-measures ANOVA was used to assess the main effects of time and visit and the 285 
time x visit interaction for [NO3
-], [NO2
-], and blood pressure variables. A one-way repeated 286 
measures ANOVA was used to determine whether there were differences in the abundance of 287 
each genus of bacteria across the three trials. The between trial differences in the Shannon 288 
diversity index was assessed using a Friedman’s rank test. Post-hoc analysis was conducted 289 
following a significant main effect or interaction using paired samples t-tests with Bonferroni 290 
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correction for multiple pairwise comparisons. Correlation coefficients (Pearson’s for 291 
normally distributed data and Spearman’s Rho for non-normally distributed data) were used 292 
to assess the association between the concentration of NO metabolites and the abundance of 293 
species specific NO3
--reducing bacteria. Using the same analyses, associations of between-294 
trial differences (Δ) in these parameters were also analysed. Statistical significance was 295 
declared when P<0.05.  296 
 297 
2.9.1. Inter-individual variation 298 
The inter-individual coefficient of variation (CVI) was calculated using the pooled mean ± 299 
SD of the three-trial average using the following equation: 300 
CVI (%) = 100 – (SD/mean) 301 
Where SD = the between participant standard deviation  302 
Where mean = the average of all participant  303 
 304 
2.9.2. Analytical variation 305 
The CVA was calculated using the pooled mean ± SD of each duplicate/triplicate measure 306 
using the following equation: 307 
CVA (%) = 100  ̶  (SD/mean) 308 
Where SD and mean are the standard deviation and the mean duplicate/triplicate measures of 309 
the same time point, respectively. 310 
 311 
 312 
15 
 
2.9.3. Biological variation 313 
The CVB for all measured variables was calculated using the mean ± SD of three samples 314 
from each participant at each time point of the experiment using the following equation: 315 
CVB (%) = 100  ̶  (SD/mean) 316 
Where SD and mean are the standard deviation and mean of repeated measures of the same 317 
time point of separate laboratory visits. 318 
 319 
2.9.4. Intra-individual variation 320 
The within subject coefficient of variation (CVW) was calculated using the following 321 
equation:   322 
CVW (%) = CVB – CVA 323 
 324 
2.9.5. Critical difference 325 
The CD was assessed using the equation of Fraser and Fogarty (1989): 326 
CD = k√CVA2 + CVW2 327 
Where k = Constant determined by the probability level (2.77 at P<0.05) 328 
 329 
3. Results 330 
3.1. Nitrate and nitrite in biological fluids   331 
The three-trial mean ± SD, CVI, CD, and residuals (CVA and CVB) for each measurement are 332 
displayed in Tables 1 and 2. Inter-individual data and group mean ± SD are presented in 333 
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Figure 2 and 3 for plasma and saliva, respectively. The CVA for the measurement of [NO3
-] 334 
(range 1.0 – 4.1%) and [NO2-] (range 1.2 – 3.9%) indicates good precision for these analyses. 335 
There was a significant main effect of ‘time’ (P<0.01) but no effect of ‘visit’ or a ‘time x 336 
visit’ interaction (P>0.05) for plasma and salivary [NO3-] and [NO2-]. Post-hoc analyses 337 
showed that baseline values were significantly lower (all P<0.01) than at all other time points 338 
that followed the ingestion of BR. Plasma [NO3
-] was significantly higher at the 2 h 339 
measurement point compared to 2.5 and 3 h post ingestion (both P<0.05).  340 
 341 
Within-participant comparisons demonstrate that total urinary NO3
- excretion did not differ 342 
between the three laboratory visits (P>0.05) (Table 1). The CVB for salivary, plasma, and 343 
urinary [NO3
-] variables ranged from 3.8 to 15.3% (Table 1). There was a greater degree of 344 
heterogeneity in saliva and plasma [NO2
-] which ranged from 9 to 32.5 % (Table 2). The CD 345 
values were also considerable for [NO3
-] variables (8.4 – 37.9%) and [NO2-] variables (19.3 – 346 
86.5%). Between-participant comparisons reveal that, as expected, the CVI was substantial, 347 
with [NO3
-] variables ranging from 18.6 to 49.1% and [NO2
-] from 29.9 to 73.5%.  348 
 349 
3.2. Abundance of nitrate-reducing bacteria 350 
After quality filtering the data and removal of singleton reads, tongue scrapings of 9 351 
participants over three separate trials were included in the analysis. Alpha diversity metrics 352 
revealed that the Shannon diversity index for the whole group across all three visits was 5.4 ± 353 
0.4 with 1356 ± 171 observed species. The Shannon diversity index did not differ between 354 
trials (P=0.50). There were 117 genera of bacteria detected in the samples. The only genera 355 
of bacteria where the abundance changed significantly was Peptostreptoccocus which was 356 
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more abundant in visit one compared to visit two (P=0.03). Previous research has shown that 357 
Peptostreptoccocus species do not have NO3
- reductase activity (Smith et al. 1999). 358 
All of the genera that have previously been implicated in NO3
- reduction (Hyde et al. 2014a) 359 
were detected in our analyses (Table 3). Prevotella was the most abundant genera and had the 360 
lowest CVB (22.7%) whilst Haemophilus, the fourth most abundant NO3
--reducing genera, 361 
had the highest CVB (77.6%). Seven of the bacterial species previously implicated in NO3
- 362 
reduction (Doel et al. 2005; Hyde et al. 2014a) were detected in the samples and the variation 363 
in the relative abundance of these species were analysed across the three visits (Fig. 4). 364 
Further analyses at the species level showed that the sum of the NO3
--reducing bacteria had a 365 
CVB of 19.5%. The CVB of individual species showed that Rothia dentocariosa and 366 
Haemophilus parainfluenzae were the most variable (132.1 and 78.6%, respectively, Table 367 
4). The two most abundant species, Prevotella melaninogenica and Veillonella dispar, had 368 
the lowest CVB of 37 and 35.1 %, respectively.  369 
 370 
3.3. Blood pressure 371 
Blood pressure data are presented alongside the variability metrics in Table 5. The CVA for 372 
the measurement of systolic blood pressure (range 1.3 – 3.8%), diastolic blood pressure 373 
(range 2.5 – 3.6%), and MAP (range 2.2 – 3.7%) indicates good precision for these 374 
parameters. There was a significant main effect of ‘time’ for systolic blood pressure 375 
(P<0.01), diastolic blood pressure (P=0.04), and MAP (P<0.01) but no ‘time x visit’ 376 
interaction (all P>0.05). There was no main effect of ‘visit’ for systolic blood pressure or 377 
MAP (P>0.05) but there was an effect of ‘visit’ on diastolic blood pressure (P=0.02). Post-378 
hoc analyses showed that systolic blood pressure was significantly lower at all measurement 379 
points following BR ingestion (all P<0.05). Diastolic blood pressure was not different 380 
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between measurement points or individual visits (all P>0.05). MAP was not different to 381 
baseline after 2 h (P=0.08) but was lower than baseline at 2.5 and 3 h post BR ingestion (both 382 
P<0.05). Measurements of systolic blood pressure (range 2.0 – 3.4%) and MAP (range 2.9 – 383 
3.9%) had minimal CVB. The CVB for diastolic blood pressure was greater, ranging from 4.2 384 
to 6.0%. Values of CD ranged from 5.3 to 11.9% for all blood pressure markers and values of 385 
CVI ranged from 4.7 to 8.1%.  386 
 387 
3.4. Association between nitrate and nitrite in biological fluids and the abundance of nitrate-388 
reducing bacteria  389 
The sum of the NO3
--reducing bacteria was not associated with measurements of [NO2
-] at 390 
any time point (all P>0.2). Individual species analysis showed that the abundance of 391 
Neisseria subflava was negatively associated with peak salivary [NO2
-] (R=-0.43, P=0.03, 392 
Fig. 5) and plasma [NO2
-] (R=-0.43, P=0.03, Fig. 5). There were no other associations 393 
between the concentration of NO metabolites and the abundance of all other individual 394 
species of NO3
--reducing bacteria (all P>0.07). The between-trial Δ in salivary [NO2-] 395 
following BR and the between-trial Δ Rothia mucilaginosa abundance were significantly 396 
associated (R=0.49, P=0.01, Fig. 6). The between-trial Δ Haemophilus parainfluenzae 397 
abundance was negatively associated with the between-trial Δ plasma [NO2-] at 3 h post BR 398 
ingestion (R=-0.4, P=0.04, Fig. 6). There were no other relationships between the variation in 399 
[NO2
-] variables and the abundance of NO3
- reducing species (all, P>0.09).  400 
 401 
 402 
 403 
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 404 
 405 
Table 1. Three-trial mean ± SD, analytical variation (CVA), biological variation 406 
(CVB), critical difference (CD), and inter-individual variability (CVI) for plasma, 407 
salivary and urinary [NO3
-] at each measurement point. * denotes significant 408 
difference compared to baseline (P<0.001).  409 
Parameter Mean ± SD 
 
CVA (%) CVB (%) CD (%) CVI (%) 
Plasma baseline 33.2 ± 7.6 μM 4.1 11.9 24.4 
 
22.8 
Plasma 2 h 452.1 ± 83.9 μM* 1.0 3.8 8.4 18.5 
Plasma 2.5 h 415.0 ± 92.2 μM* 1.2 4.7 10.3 22.2 
Plasma 3 h 391.6 ± 99.2 μM* 1.8 8.8 19.9 25.3 
Saliva baseline 0.5 ± 0.2 mM 2.1 15.3 37.1 30.7 
Saliva 2.5 h 8.5 ± 2.1 mM* 1.4 12.0 29.7 24.1 
Urine total  1.7 ± 0.3 g (x10-4) 1.7 15.3 37.9 49.1 
 410 
Table 2. Three-trial mean ± SD, analytical variation (CVA), biological variation 411 
(CVB), critical difference (CD), and inter-individual variability (CVI) for plasma and 412 
salivary [NO2
-] at each measurement point. * denotes significant difference 413 
compared to baseline (P<0.001). 414 
Parameter Mean ± SD CVA (%) CVB (%) CD (%) CVI (%) 
Plasma baseline 124.2 ± 48.8 nM 2.5 9.0 19.3 39.3 
Plasma 2 h 284.9 ± 83.5 nM* 2.1 19.3 47.9 29.3 
Plasma 2.5 h 278.6 ± 73.9 nM* 2.4 18.6 45.4 26.5 
Plasma 3 h 323.9 ± 94.1 nM* 2.2 20.6 51.3 29.0 
Saliva baseline 135.7 ± 99.8 μM 1.2 32.5 86.5 73.5 
Saliva 2.5 h 903.6 ± 267.6 μM* 3.9 24.5 58.1 29.6 
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 415 
 416 
Figure 2. Group mean ± SD and inter-individual variation across the three identical trials for 417 
plasma [NO3
-] at baseline (A), 2 h (B), 2.5 h (C), and 3 h (D), and for plasma [NO2
-] at 418 
baseline (E), 2 h (F), 2.5 h (G), and 3 h (H). All post supplementation time points for plasma 419 
[NO3
-] and [NO2
-] were significantly elevated compared to baseline concentrations (all P < 420 
0.01). 421 
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 422 
Figure 3. Group mean ± SD and inter-individual variation across the three identical trials for 423 
salivary [NO3
-] at baseline (A), and 2.5 h (B), and for salivary [NO2
-] at baseline (C), and 2 h 424 
(D). Following supplementation salivary [NO3
-] and [NO2
-] were significantly elevated 425 
compared to baseline concentrations (all P < 0.01). 426 
 427 
 428 
 429 
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 430 
Figure 4. A comparison of the relative abundance of NO3
--reducing species between three 431 
identical trials taken at baseline during each laboratory visit. Data are presented as group 432 
means with SD excluded for clarity.  433 
 434 
 435 
436 
Figure 5. Correlations between Neisseria subflava and peak concentration plasma [NO2
-] (A) 437 
and salivary [NO2
-] (B).  * denotes significant difference.  438 
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 439 
Figure 6. Correlations between ∆ plasma [NO2-]/∆ Haemophilus parainfluenzae (A) and ∆ 440 
salivary [NO2
-]/∆ Rothia mucilaginosa (B).  * denotes significant difference. 441 
 442 
Table 3. Relative abundance of genera previously implicated in NO3
- 443 
reduction and the corresponding biological variation (CVB) and inter-444 
individual variability (CVI). 445 
OTU ID Mean ± SD (%) 
  
CVB (%) CVI (%) 
Prevotella 35.6 ± 13.5 22.7 38.6 
Veillonella 14.7 ± 7.2 33.4 50.1 
Fusobacterium 9.5 ± 9.3 54.5 97.8 
Haemophilus 6.5 ± 11.1 77.6 145.0 
Leptotrichia 6.4 ± 3.6 52.7 56.1 
Streptococcus 2.0 ± 1.9 45.7 96.8 
Neisseria 1.8 ± 2.5 67.9 130.7 
Porphyromonas 1.6 ± 1.8 76.1 119.4 
Actinomyces 1.0 ± 0.8 64.5 82.8 
Rothia 0.2 ± 0.2 57.7 108.6 
Granulicatella 0.1 ± 0.2 72.0 122.9 
 446 
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Table 4. Relative abundance of species previously implicated in NO3
- reduction and 447 
the corresponding biological variation (CVB) and inter-individual variability (CVI). 448 
Species Mean ± SD (%) 
  
CVB (%) CVI (%) 
Prevotella melaninogenica 23.8 ± 6.4 37.0 26.9 
Veillonella dispar 13.0 ± 4.0 35.1 30.7 
Haemophilus parainfluenzae 6.5 ± 5.9 78.6 90.7 
Neisseria subflava  1.7 ± 1.0 70.0 57..7 
Veillonella parvula 0.9 ± 0.4 43.2 44.3 
Rothia mucilaginosa  0.2 ± 0.1 60.0 41.0 
Rothia dentocariosa <0.01 ± <0.01 132.1 118.4 
 449 
  450 
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Table 5. Three-trial mean ± SD, analytical variation (CVA), biological 451 
variation (CVB), critical difference (CD), and inter-individual 452 
variability (CVI) for blood pressure parameters at each measurement 453 
point. * denotes significant difference compared to baseline (P<0.05). 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
4. Discussion 465 
The present study demonstrates that, as hypothesised, the concentration of NO3
- and 466 
conversion to NO2
- in biological fluids varies substantially within individuals across repeated 467 
laboratory visits under the same conditions. Likewise, the CVB for the abundance of NO3
--468 
reducing bacteria were also profound, suggesting substantial heterogeneity in these 469 
measurements. The CD values for NO metabolites at baseline suggest that large relative 470 
changes in these parameters are required before a meaningful difference can be concluded 471 
following an intervention. On the other hand, measurements of blood pressure at baseline 472 
Blood Pressure Mean ± SD 
(mmHg) 
CVA (%) CVB (%) CD (%) CVI (%) 
Systolic baseline 126 ± 7 1.9 2.0 5.3 5.9 
Systolic 2 h 121 ± 7* 1.3 3.1 6.1 6.1 
Systolic 2.5 h 120 ± 7* 3.8 3.4 10.6 6.4 
Systolic 3 h 122 ± 7* 3.3 3.2 10.1 5.8 
Diastolic baseline 70 ± 5 3.4 4.8 10.2 7.7 
Diastolic 2 h 67 ± 5 3.0 4.9 9.9 8.1 
Diastolic 2.5 h 67 ± 4 3.6 4.2 10.2 5.  
Diastolic 3 h 67 ± 4 2.5 6.0 11.9 6.2 
MAP baseline 88 ± 5 2.7 3.9 8.1 5.4 
MAP 2 h 85 ± 5 2.2 3.4 7.0 5.9 
MAP 2.5 h 85 ± 4* 3.7 3.1 10.4 5.0 
MAP 3 h  85 ± 4* 3.1 2.9 8.5 4.7 
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demonstrated much lower CVB across repeated trials. The relative abundance of Neisseria 473 
subflava on the tongue was negatively associated with [NO2
-] in the saliva and plasma 474 
following ingestion of BR. The variation in salivary [NO2
-] following BR between repeated 475 
trials was also associated with the variation in the abundance of Rothia mucilaginosa and the 476 
between-trial variation in peak plasma [NO2
-] was negatively associated with the variation in 477 
the abundance of Haemophilus parainfluenzae. These data suggest that, contrary to our 478 
hypothesis, the CVB of NO metabolites is only partly accounted for by the CVB in the 479 
abundance of NO3
--reducing bacterial species.  480 
 481 
4.1. Variability of the tongue microbiome of healthy humans 482 
There were 1356 ± 171 observed species of bacteria in the tongue scrape samples across the 483 
three trials which is comparable with some (Li et al. 2014; Burleigh et al. 2018) and 484 
considerably higher than others (Hyde et al. 2014a). The Shannon Diversity Index, which 485 
accounts for both richness and evenness of OTUs, was also similar to previous reports in 486 
healthy humans (Zaura et al. 2009; Hyde et al. 2014a; Burleigh et al. 2018). Veillonella is 487 
commonly reported to be the most abundant of the taxa that are specifically implicated in 488 
NO3
- reduction  (Doel et al. 2005; Hyde et al. 2014a). In the present study, however, 489 
Prevotella were found to be more than twice as abundant as Veillonella. These dissimilarities 490 
are likely explained by inter-individual differences in study cohorts as corroborated by the 491 
profound CVI across all genera previously implicated in NO3
- reduction (Table 3). In line 492 
with our previous work (Burleigh et al. 2018), Prevotella melaninogenica and Veillonella 493 
dispar were the most abundant species of NO3
--reducing bacteria in all three trials.  494 
 495 
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The inter-individual diversity and temporal dynamics of tongue microbiota in the oral 496 
cavity has previously been investigated by Hall and colleagues (2017) who collected 497 
samples daily, weekly, and monthly from 10 healthy participants. There was significant 498 
drift in the composition of the microbiome over both short and long time scales, the 499 
magnitude of which varied between subjects. Nevertheless, several species were 500 
consistently observed (≥ 95% samples) at all measurement points, including several 501 
species that have been implicated in NO3
- reduction (Haemophilus parainfluenzae, Neisseria 502 
subflava, and Rothia dentocariosa). In the present study, the CVB for seven of the bacteria 503 
previously implicated in NO3
- reduction are reported for the first time. Here, we show that 504 
there is profound within-participant variation at both the level of genera (23 – 78%) and 505 
species (35 – 132%) at three controlled measurement points over a 15-21 day period. This 506 
may be reasonably expected given that the mouth is exposed to  the external environment 507 
and regularly subjected to brushing, flossing, and nutrient intake (Hall et al. 2017) which 508 
may consequently influence pH (Krulwich et al. 2011). It has been shown previously that 7 509 
days of sodium NO3
- supplementation (Hyde et al. 2014b) and 10 days (Vanhatalo et al. 510 
2018) or 6 weeks (Velmurugan et al. 2016) of BR supplementation  results in significant 511 
alterations to the oral microbiome, including species of NO3
--reducing bacteria. Our study 512 
demonstrates that despite standardising diet, physical activity, mouthwash, teeth brushing, 513 
and tongue cleaning before each trial, the abundance of these bacteria vary considerably. 514 
Quantifying the magnitude of this variation provides useful metrics which will aid 515 
researchers to interpret the meaningfulness of changes to the oral microbiome following an 516 
intervention.   517 
 518 
 519 
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 520 
4.2. Variability in the measurements of nitric oxide metabolites 521 
Values of plasma and salivary [NO2
-] and [NO3
-] at baseline and following the ingestion of 522 
BR are broadly in line with those reported in the literature (e.g. James et al. 2015; Liddle et 523 
al. 2018; Woessner et al. 2016). Some of the subtle differences between studies may be partly 524 
explained by dissimilarities in methodology and study control (Bryan et al. 2007; Feelisch et 525 
al. 2010; Liddle et al. 2018). Inter-individual differences between participants in each cohort 526 
will also likely underpin some of the variation in basal NO metabolite concentration and NO 527 
pharmacokinetics following the ingestion of BR (Muggeridge et al. 2014; James et al. 2015; 528 
McIlvenna et al. 2017). This is highlighted profoundly by the CVI values in the current data 529 
set which were 19 – 31% for salivary and plasma NO3- and 27 – 74% for NO2-. Porcelli and 530 
colleagues (2015) have demonstrated that physical fitness appears to affect the response to 531 
NO3
- supplementation whereby the increase in plasma [NO2
-] is suppressed in individuals 532 
with better aerobic fitness. Alternatively, other factors which may influence endogenous 533 
production of NO (Luiking et al. 2010) or differences in the oral (Burleigh et al. 2018) and 534 
gut microbiota (Flint et al. 2012) may also account for some of the inter-cohort variations. 535 
For example, we have recently demonstrated that individuals with a higher abundance of 536 
NO3
--reducing bacteria generate more NO2
- in the saliva and at a faster rate (Burleigh et al. 537 
2018).  538 
 539 
Given the exponential rise in research exploring the health promoting and ergogenic effects 540 
of BR it is perhaps surprising that the CVB for the physiological responses to this 541 
supplementation regimen have not previously been reported. Particularly where it is argued 542 
that changes in any outcome should be interpreted within the boundaries of CD  in order to 543 
quantify a meaningful  difference (Fraser and Fogarty 1989). At baseline, there was moderate 544 
29 
 
CVB in plasma markers (9 and 12% for NO2
- and NO3
-, respectively) although the variation 545 
was more substantial in salivary measures (33 and 15% for NO2
- and NO3
-, respectively). 546 
Following the ingestion of BR, the CVB of NO3
- ranged from 4 – 9% in plasma and 12 – 15% 547 
in saliva which was considerably lower than the CVB of NO2
- markers (19 – 21% in plasma 548 
and 25 – 33% in saliva). Urinary excretion of NO3- was also shown to have a large CVB 549 
(15%) and CVI (49%).  The CD values demonstrate that substantial changes in NO markers 550 
in biological fluids are required at baseline or following the ingestion of BR to be deemed 551 
biologically meaningful (Fraser and Fogarty 1989).  552 
 553 
4.3. Association between nitrate-reducing bacteria and nitric oxide metabolites 554 
The oral microbiome is known to be a crucial component of the NO3
--NO2
--NO pathway. 555 
Abolishing oral bacterial species with anti-bacterial mouthwash, for example, has been 556 
shown to substantially interrupt oral reductase capacity (Kapil et al. 2013; Bondonno et al. 557 
2015; McDonagh et al. 2015; Woessner et al. 2016). Given the oral microbiome is 558 
exceptionally sensitive and modifiable within individuals, it is plausible that intra-individual 559 
variations in the abundance of NO3
--reducing bacteria would influence circulating levels of 560 
NO2
- and NO metabolite pharmacokinetics following the ingestion of BR. A large CVB in 561 
[NO2
-] values would, therefore, be reasonably expected given the large CVB in the abundance 562 
of NO3
--reducing bacteria. Further analyses of our data reveals that variation in oral 563 
microbiota do influence the CVB of the NO metabolites, at least to some extent. The relative 564 
abundance of Neisseria subflava on the tongue was negatively associated with the peak [NO2
-565 
] in the saliva and plasma following ingestion of BR. The Δ in salivary [NO2-] following BR 566 
between repeated trials was also positively associated with the between-trial Δ in Rothia 567 
mucilaginosa. Additionally, the between-trial Δ in plasma [NO2-] at 3 h post BR ingestion 568 
was negatively associated with the between-trial Δ in Haemophilus parainfluenzae. Whilst it 569 
30 
 
is possible that these species may be particularly important for NO3
- reduction, it must be 570 
acknowledged that all statistically significant associations were only “moderate” in strength 571 
(R = 0.40 – 0.49), are likely underpowered, and do not necessarily imply “cause-effect”. 572 
Furthermore, while the dorsal surface of tongue is the area of the oral cavity in which the 573 
majority of NO3
- reduction activity occurs (Doel et al. 2005), our sampling of the oral 574 
microbiome was not comprehensive. For example, NO3
- reduction is also reported to occur 575 
directly in the saliva (Goaz and Biswell 1961) and in other areas of the mouth. It is also 576 
recognised that some species of bacteria are capable of reducing NO2
- to NO in the saliva and 577 
the abundance of these microbiota may be considered to influence plasma [NO2
-]. However, 578 
NO2
-  reduction via bacterial enzymatic activity is a slow process (Doel et al. 2005) and, 579 
given the rapid extrusion of NO2
-  through continuous swallowing, the abundance of these 580 
microbiota are likely to be less relevant.   581 
 582 
While the relevant abundance of the oral microbiome seems to contribute towards the 583 
regulation of NO bioavailability (Burleigh et al. 2018), it does not fully account for the large 584 
CVB in basal [NO2
-] and [NO3
-] and the variable response to ingested inorganic NO3
-. Indeed, 585 
the metabolic activity of the NO3
--reducing bacteria may be more important than the relevant 586 
abundance (Hyde et al. 2014a). Alternatively, CVB of other factors including the 587 
aforementioned abundance and activity of gut bacteria, stomach pH (Lundberg et al. 1994; 588 
Montenegro et al. 2017), rates of gastric emptying and intestinal absorption (Leiper 2015), or 589 
the availability of sialin, a NO3
- transporter in the saliva (Qin et al. 2012), may also contribute 590 
towards a high CVB in NO metabolism. There also seems to be circadian variation in 591 
endogenous NO production (Antosova et al. 2009). Furthermore, while participants were 592 
requested to replicate their diet prior to each trial, the NO3
- content of regularly consumed 593 
vegetables is known to vary considerably (Lidder and Webb 2013). Non-compliance with 594 
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these instructions also cannot be ruled out although all participants gave verbal assurances on 595 
this point. Exposure to different doses of sunlight has also been shown to influence 596 
circulating levels of NO2
- (Monaghan et al. 2018). However, the latter mechanism may have 597 
had minimal influence in the present study as data were collected in the autumn/winter 598 
months. Establishing the independent contribution of each of these factors to NO 599 
bioavailability will be a difficult task due to a lack of gold-standard measurements or 600 
challenges in isolating each as an independent variable rather than a covariate.  601 
 602 
4.4. Variability in the blood pressure response to nitrate supplementation 603 
Ingestion of BR resulted in significant reductions in systolic blood pressure and MAP which 604 
supports findings from a recent meta-analysis showing a mean reduction in systolic blood 605 
pressure of 4.4 mmHg (Siervo and Lara 2013). Novel data in this study shows that the 606 
reduction in blood pressure markers is consistently observed in response to NO3
- 607 
supplementation and, in contrast to NO metabolites, the CVB for these measurements are 608 
relatively low (all <5%). This contrasts with previous research which reports the visit-to-visit 609 
variation is larger (>8%) for systolic and diastolic blood pressure in various clinical cohorts 610 
(Marshall 2004; Howard and Rothwell 2009). In absolute terms, baseline systolic blood 611 
pressure (mean 126 ± 7 mmHg) varied by 2.5 mmHg across the three trials of the present 612 
study compared to 14.7 mmHg (mean 147 ± 18.4 mmHg) in patients who had suffered a 613 
minor transient ischemic attach or minor ischemic stroke (Howard and Rothwell 2009). This 614 
suggests that cohorts with a higher blood pressure will also have an increased CVB for this 615 
metric. Indeed, an increased variability CVB may also have some prognostic value as it has 616 
been associated with the development, progression, and severity of cardiac, vascular, and 617 
renal damage and with an increased risk of cardiovascular events and mortality (Parati et 618 
al. 2013). It is important to highlight that the participants in the present study were all 619 
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from a homogenous cohort; namely they were all healthy Caucasian males from a 620 
relatively narrow age range. It is likely that CVB and CD for all measured outcomes would 621 
increase in a more heterogonous group of healthy participants which included females and 622 
older adults.    623 
Webb and colleagues (2008) have previously reported that ingestion of BR reduces systolic 624 
blood pressure by up to ~10 mmHg in healthy participants. Notably, the magnitude of this 625 
reduction in systolic blood pressure exceeds the baseline CD reported here (6.7 mmHg, 5.3 626 
%) which confirms that this is a meaningful change in this parameter. In contrast, the BR-627 
induced reduction in blood pressure reported in this study and more widely across the 628 
literature in healthy normotensive participants (Siervo and Lara 2013) are typically smaller 629 
and do not exceed the CD threshold. In patients with stage 1 hypertension, a single dose of 630 
NO3
--rich BR reduced systolic blood pressure by 11 mmHg (7.3%) (Ghosh et al. 2013) 631 
suggesting the effects of BR are more pronounced in those with an elevated blood pressure. 632 
However, given that a high blood pressure will also elevate the CVB, researchers should be 633 
cautious about using CD values generated from healthy participants to interpret data in 634 
hypertensive or diseased cohorts. While this does not rule out a therapeutic effect of 635 
inorganic NO3
- supplementation in hypertensive patients, the potential influence of CVA and 636 
CVB on experimental outcomes should be duly considered when interpreting the data.   637 
 638 
5. Conclusion  639 
The data in the current study demonstrates that there is profound intra-individual variability 640 
in the measurement of NO metabolites in plasma and saliva, both at basal levels and when 641 
elevated following ingestion of BR. While the change in the abundance of certain species of 642 
NO3
--reducing bacteria appears to account for some of this variation, other biological and 643 
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experimental factors are also likely to contribute. Markers of blood pressure were 644 
consistently reduced on three separate occasions following the ingestion of BR but the 645 
magnitude of the change was small and did not exceed the CD. The data presented in this 646 
manuscript presents metrics which facilitate a more meaningful interpretation of changes in 647 
key physiological variables following dietary NO3
- supplementation. 648 
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